Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.39 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27057838 | 1.00 | RORC (0.39) | RORCCCRL2SYKSCN9AMAP4K4 | |
| SCHEMBL27057834 | 0.90 | RORC (0.38) | RORCCCRL2SYKSCN9AGPR119 | |
| SCHEMBL25332512 | 0.87 | NOTUM (0.36) | SCN9AHDAC6GRM2 | |
| SCHEMBL25330027 | 0.83 | TEAD1 (0.45) | SCN9A | |
| SCHEMBL30576479 | 0.83 | TEAD1 (0.45) | SCN9A | |
| SCHEMBL27057237 | 0.82 | CCRL2 (0.39) | RORCCCRL2 | |
| SCHEMBL30767959 | 0.82 | CCRL2 (0.39) | RORCCCRL2 | |
| SCHEMBL27057835 | 0.80 | SYK (0.38) | RORCCCRL2SYKMAP4K4GPR119 | |
| SCHEMBL27057831 | 0.80 | SLC6A2 (0.35) | SCN9AGPR119HDAC4HDAC6 | |
| SCHEMBL27057233 | 0.80 | RORC (0.38) | RORCCCRL2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | RORC 426/4885CCRL2 2935/4885SYK 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.